ID
13483
Description
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: M6 Bone Marrow Evaluation Form
Keywords
Versions (3)
- 11/10/15 11/10/15 -
- 12/23/15 12/23/15 -
- 2/11/16 2/11/16 -
Uploaded on
February 11, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
M6 Bone Marrow Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26
M6 Bone Marrow Evaluation Form
- StudyEvent: ODM
Description
Comment
Similar models
M6 Bone Marrow Evaluation Form
- StudyEvent: ODM
C0220825 (UMLS CUI-2)
C2348792 (UMLS CUI [1,2])
C1964257 (UMLS CUI-2)
C0011008 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,2])